Valuation : Verrica Pharmaceuticals Inc.

Market Cap 91.05M 78.3M 73.64M 67.23M 126M 8.61B 126M 873M 338M 4.41B 342M 334M 14.05B P/E 2026 *
-2.59x
P/E 2027 * -3.54x
Enterprise Value 91.05M 78.3M 73.64M 67.23M 126M 8.61B 126M 873M 338M 4.41B 342M 334M 14.05B EV / Sales 2026 *
3.67x
EV / Sales 2027 * 2.32x
Free-Float
50.97%
Yield 2026 *
-
Yield 2027 * -
08-28 Lake Street Initiates Verrica Pharmaceuticals at Buy With $9 Price Target MT
08-27 Verrica Pharmaceuticals Completes Enrollment in First Pivotal Phase 3 Trial (Cove-2) Evaluating Ycanth for the Treatment of Common Warts CI
08-06 Verrica Pharmaceuticals Inc., Q2 2026 Earnings Call, Aug 06, 2026
08-06 Verrica Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
08-06 Verrica Pharmaceuticals Inc. Closes Credit Facility for Up to $27.5 Million in Non-Dilutive Growth Capital CI
07-21 Verrica Pharmaceuticals Inc. and Medomie Pharma Ltd. Enters into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH for Treatment of Molluscum Contagiosum in Israel CI
07-21 Verrica Pharmaceuticals Signs Distribution Deal With Medomie for Molluscum Treatment MT
06-29 Verrica Pharmaceuticals Inc.(NasdaqCM:VRCA) added to Russell 3000E Growth Benchmark CI
06-29 Verrica Pharmaceuticals Inc.(NasdaqCM:VRCA) added to Russell 3000E Index CI
06-29 Verrica Pharmaceuticals Inc.(NasdaqCM:VRCA) added to Russell Microcap Index CI
06-28 Verrica Pharmaceuticals Inc.(NasdaqCM:VRCA) added to Russell Microcap Growth Benchmark Index CI
06-22 Verrica Pharmaceuticals Announces First U.S. Patient Dosed in Second Pivotal Clinical Trial (Cove-3) of Its Phase 3 Program Evaluating Ycanth (Vp-102) for Treatment of Common Warts CI
06-22 Verrica Pharmaceuticals' Doses First US Patient in Phase 3 Trial Evaluating Ycanth to Treat Common Warts MT
1 day-1.12%
1 week-2.93%
Current month-2.93%
1 month+4.33%
3 months-12.25%
6 months-0.19%
Current year-36.22%
1 week 5.25
Extreme 5.25
5.63
1 month 4.61
Extreme 4.61
5.86
Current year 4.24
Extreme 4.245
8.95
1 year 3.28
Extreme 3.28
9.82
3 years 3.28
Extreme 3.28
114.1
5 years 3.28
Extreme 3.28
136.4
10 years 3.28
Extreme 3.28
232.9
Manager TitleAgeSince
Chief Executive Officer 50 2024-11-04
Director of Finance/CFO 54 2024-11-04
Chief Tech/Sci/R&D Officer 59 2025-03-25
Director TitleAgeSince
Chairman 70 2017-11-30
Director/Board Member 56 2015-11-30
Director/Board Member 60 2018-04-30
Date Insider Type Main position Quantity % Market Cap. Importance
8/18/26 Buy

Chief Financial Officer

5,000 0.0291%
8/18/26 Buy

Chief Technology Officer

2,030 0.0118%
8/17/26 Buy

Chief Operating Officer

6,000 0.0349%
Change 5-day change 1-year change 3-year change Capi.($)
-1.12%-2.93%+3.82%-87.32% 91.05M
-0.88%-0.64%+58.05%+100.51% 1,024B
-1.15%+3.53%+54.25%+71.99% 663B
-1.44%+0.02%+20.65%+72.22% 453B
-0.95%+0.23%+28.96%+37.78% 352B
-3.18%+1.78%+20.66%+41.55% 304B
+0.30%+0.60%-0.40%+11.25% 252B
-1.55%+1.71%+54.15%+71.87% 236B
+0.02%+2.24%-14.59%-55.80% 206B
-0.15%+3.18%+31.24%+104.21% 187B
Average -1.01%+0.48%+25.68%+36.83% 367.85B
Weighted average by Cap. -1.07%+0.64%+37.20%+64.50%

Financials

2026 *2027 *
Net sales 24.82M 21.34M 20.08M 18.33M 34.27M 2.35B 34.38M 238M 92.01M 1.2B 93.21M 91.17M 3.83B 39.22M 33.73M 31.72M 28.96M 54.16M 3.71B 54.33M 376M 145M 1.9B 147M 144M 6.05B
Net income -46.08M -39.63M -37.28M -34.03M -63.64M -4.36B -63.85M -442M -171M -2.23B -173M -169M -7.11B -38.03M -32.71M -30.76M -28.08M -52.52M -3.6B -52.69M -365M -141M -1.84B -143M -140M -5.87B
Net Debt - -
Logo Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc. is a dermatology therapeutics company developing and selling medications for skin diseases requiring medical intervention. The Company's product portfolio consists of one approved product with several potential follow-on indications, as well as an additional pipeline product. Its commercial product, YCANTH (VP-102), is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin. YCANTH (VP-102) is being developed for the treatment of molluscum contagiosum in adult and pediatric patients two years of age and older. It is also engaged in developing YCANTH (VP-102) for a potential follow-on indication for the treatment of common warts. Its second development candidate, VP-315, is an oncolytic peptide-based injectable therapy for the potential treatment of dermatology oncologic conditions, including basal cell carcinoma (BCC).
Employees
76
Date Price Change Volume
26-09-04 US$5.300 -1.12% 12,197
26-09-03 US$5.360 -0.56% 55,385
26-09-02 US$5.390 +2.86% 31,077
26-09-01 US$5.240 -4.03% 43,490
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
5.300USD
Average target price
13.83USD
Spread / Average Target
+161.01%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. VRCA Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!